Duchenne muscular dystrophy (DMD) is a hereditary disease caused by mutations that disrupt the dystrophin mRNA reading frame. In some cases, forced exclusion (skipping) of a single exon can restore the reading frame, giving rise to a shorter, but still functional, protein. In this study, we constructed lentiviral vectors expressing antisense oligonucleotides in order to induce an efficient exon skipping and to correct the initial frameshift caused by the DMD deletion of CD133+ stem cells. The intramuscular and intra-arterial delivery of genetically corrected CD133 expressing myogenic progenitors isolated from the blood and muscle of DMD patients results in a significant recovery of muscle morphology, function, and dystrophin expression in scid/mdx mice. These data demonstrate that autologous engrafting of blood or muscle-derived CD133+ cells, previously genetically modified to reexpress a functional dystrophin, represents a promising approach for DMD.
INTRODUCTION
Duchenne muscular dystrophy (DMD) is characterized by a lack of dystrophin protein at the sarcolemma of muscle fibers (Hoffman et al., 1987; Watkins et al., 1988) , a condition that results clinically in progressive muscle weakness associated with chronic degeneration and regeneration of skeletal myofibers. The lack of dystrophin expression arises from mutations that disrupt the production of a translatable transcript from the dystrophin gene, most commonly by deletions or duplications that cause a shift in its open reading frame. Currently there is no therapy to prevent DMD or to halt its progression. One suggested route to therapy proposes the use of viral or nonviral vectors to deliver the full-length dystrophin or one of a number of versions of mini-dystrophin gene that have been demonstrated to assuage the muscle weakness commonly observed in mdx dystrophic mice (Acsadi et al., 1996; Hartigan-O'Connor and Chamberlain, 2000; Scott et al., 2002; Lai et al., 2005; Li et al., 2006) . In this context, transgene expression persisted and prevented subsequent muscle fiber degeneration for at least 6 months Roberts et al., 2002) . Transplantation of normal myogenic cells into dystrophin-deficient is an alternative therapeutic approach, and it has been demonstrated that transplanted myogenic cells contribute to muscle regeneration giving rise to skeletal muscle fibers expressing functional dystrophin protein (Partridge et al., 1989; Huard et al., 1992 Huard et al., , 1994 Tremblay et al., 1993; Beauchamp et al., 1999; Vilquin et al., 1995; Gussoni et al., 1997 Gussoni et al., , 1999 Smythe and Grounds, 2001; Skuk et al., 2006) . However, myoblast transplantation has several limitations, including immune rejection, poor cellular survival rates, and limited dissemination of the injected cells (Huard et al., 1992 (Huard et al., , 1994 Tremblay et al., 1993; Vilquin et al., 1995; Gussoni et al., 1997; Beauchamp et al., 1999; Smythe and Grounds, 2001; Skuk et al., 2006) . Thus, alternative stem or progenitor cells with myogenic capacity are being investigated (Gussoni et al., 1999; Lee et al., 2000; Blau et al., 2001; Goodell et al., 2001; Seale et al., 2001; Jackson et al., 2002; Qu-Petersen et al., 2002; Dreyfus et al., 2004; Dezawa et al., 2005; Goncalves et al., 2006) . Among these adult stem cells, we previously showed that human blood-derived progenitors, expressing the CD133 surface marker, are able to regenerate dystrophic muscle fibers (Torrente et al., 2004) . Here, we have extended these observations to a combination of cell-and gene-based approaches via the ex vivo introduction of corrective genes into dystrophic CD133+ myogenic cells, which would permit their subsequent autologous transplantation. Use of the patient's own cells would reduce the risk of implant rejection.
As a correction method, we used the exon-skipping approach. This technology uses specific antisense oligonucleotides (AONs) designed to mask the putative splicing sites of exons in the mutated region of the primary RNA transcript whose removal would reestablish a correct reading frame. The majority of DMD mutations are localized into the central rod domain of the dystrophin where in-frame removal of central spectrin-like repeats, as in mini-or microdystrophin constructs, has been demonstrated to conserve functionality (Gregorevic and Chamberlain, 2003) ; for this reason, this protein is well suited to exon-skipping strategies.
In fact, there is a clinical trial currently underway to test the efficacy, safety, and tolerability of a single intramuscular dose of AONs to restore production of the dystrophin in DMD patients (Leiden Muscular Dystrophy page, www.dmd.nl).
Moreover, in vivo exon-skipping has previously been achieved in the mdx model through a gene therapy approach using an AAV vector to introduce and to spread the production of specific AONs through dystrophic muscles (Goyenvalle et al., 2004; Denti et al., 2006) . These results demonstrate the efficiency of this method to recover the expression of a shorter but functional dystrophin that is able to recruit its associated proteins (i.e., sarcoglycans and dystroglycans).
We have thus sought to combine cell therapy using human dystrophic blood and muscle-derived stem cells sharing the CD133 antigen and gene therapy based on exon skipping correction to deliver a functional dystrophin into the scid/mdx dystrophic mice. Both stem cell populations were transduced with a lentiviral vector expressing the U7 snRNA containing antisense sequences designed specifically to skip exon 51 and able to restore open reading frame to a range of DMD genotypes. In accordance with our hypothesis, the genetically engineered DMD stem cells expressed a shortened dystrophin mRNA specifically deleted for the exon 51. Moreover, genetically engineered DMD stem cells restore the dystrophin synthesis and contribute to the regeneration of dystrophic skeletal muscles. These data demonstrate that genetically engineered blood or muscle-derived CD133+ cells represent a possible tool for future stem cell based autografts applications in DMD.
RESULTS

Characterization of CD133+ Cells Derived from the Normal and DMD Muscles
Our previous results demonstrated the capacity of human blood CD133+ cells to participate in regeneration of dystrophic muscle (Torrente et al., 2004) . Here, we first investigated whether CD133+ human progenitors are present into skeletal muscle tissue and whether they exhibit myogenic properties. Cells were isolated from human normal and dystrophic muscles and characterized by flow cytometry (Figure 1 ). CD133+ cells isolated from normal muscle represent 1% of the total mononucleated muscle cells with no interindividual differences between the specimens (14-70 years) ( Figure 1A ). Less than 5% of the normal muscle derived CD133+ cells coexpressed the CD34 antigen, whereas $53% of them coexpressed CXCR4 ( Figure 1A ). On the other hand, dystrophic muscle FACscan immunophenotyping of the fractionated normal (A) and dystrophic (B) musclederived CD133+ cells. Less than 5% of the normal muscle-derived CD133+ cells coexpressed the CD34 antigen, whereas $53% of them coexpressed CXCR4 (A). Otherwise, more than 79% of the CD133+ cells isolated from dystrophic muscle coexpressed CD34 and CXCR4 antigens ($56%, [B] [G] ). Merging of (E) and (F) is shown in (G). After injection into dystrophic muscle, several human nuclear lamin A/C-positive cells (red in [H] ) were distributed near the capillary network (arrows) of host myofibers, coexpressing a-SMA antigen (green in [I] ). (J) shows the merging of (H) and (I). Nuclei were stained blue with Dapi.
CD133+ cells represent a range from 0.1%-5% of the total nucleated cells isolated from dystrophic muscle with significant interindividual differences between the specimens, according to the degree of muscle degeneration (5-17 years) ( Figure 1B ). More than 79% of CD133+ cells derived from dystrophic expressed CD34, whereas $56% of these cells were CXCR4 positive ( Figure 1B ). Less than 4% of the CD133+ cells isolated from either normal or dystrophic muscles were found to express the panleukocyte common antigen CD45 (data not shown). The CD133+ cells isolated from normal and dystrophic muscles proliferate well and can be expanded in vitro. Some 5% of single CD133+ cells replicated, giving rise to adherent clonal colonies (Figure 2A ). The majority of these clones appear phenotypically identical and homogeneous for marker expression. Detection by RT-PCR revealed transcripts of human MyoD, , and Myogenin, in both normal and dystrophic CD133+ populations after 24 hr of culture, suggesting a certain degree of myogenic commitment ( Figure 2H ) in comparison with blood-derived CD133+ cells that are negative for these markers (Torrente et al., 2004) . After 14 days in ''fusion-promoting,'' low-serum conditions, both normal and dystrophic muscle-derived CD133+ cells fused into multinucleated myosin+ myotubes that expressed muscle specific gene products as revealed by immunoblot analysis ( Figure 2I ). Although all clones differentiated into myotubes, they appeared heterogeneous with variability between myotubes as to the amounts a-smooth muscle actin (a-SMA) expressed (Figures 2B and 2D) .
We also investigated whether human normal and dystrophic muscle progenitors can exhibit myogenic properties in vivo after implantation into the muscle of the immunodeficient scid/mdx mice. Two months after intramuscular (i.m.) transplantation of muscle CD133+ cells, we found human spectrin+ myofibers coexpressing the human lamin A/C and with no differences between muscles injected with normal (215 ± 91 +ve myofibers per section) and dystrophic (193 ± 74 +ve myofibers per section) sources ( Figures 1C and 1D) . Moreover, several donor cells contained human lamin A/C+ nuclei and coexpressed markers of endothelial cells, CD31 and VE-cadherin ( Figures 1E-1G ), near and within small vessels in the injected area (normal and dystrophic CD133+ generated, respectively, $21% and $19% of the total . 3T3 fibroblast and G8 myoblast cell lines were used as control (lanes 3T3 and G8, respectively). Utrophin immunoblotting indicated that the same total protein concentration was present in all specimens. A tube formation assay was also used to determine the capability of conditioned muscle CD133+ cells media to regulate the angiogenesis (E and F). Capillary formation was observed when the human endothelial cells (HUVEC) were cultured with supernatant of normal (E) and dystrophic (F) muscle CD133+ cells. Induction of CD31+ capillaries in HUVEC cell cultures was quantified (G) comparing the effect of a VEGF-conditioned medium (lane VEGF, positive control) and the muscle CD133+ cell-conditioned medium (lane MDSC supernatant).
lamin A/C+ cells per cross-section). Lamin A/C+ cells expressing the a-SMA marker were also observed around muscle capillaries, suggesting a pericyte commitment ( Figures 1H-1J) . Moreover, the supernatant of muscle CD133+ cells induced the formation of CD31+ capillaries in vitro from human endothelial cells ( Figures 2E-2G ). Together, these data suggest that CD133+ cells derived from normal or dystrophic muscle have been recruited into muscle fibers and muscle vessels, indicating a myoendothelial progenitor status.
U7 Exon 51 Lentivirus Vector Induce an Efficient
Exon Skipping in Blood-and Muscle-Derived CD133+ DMD Cells In Vitro As a possible treatment for dystrophic muscles, we investigated the combination of exon skipping and cell-based therapy. Blood-and muscle-derived CD133+ cells, obtained from a DMD patient exhibiting a frame shifting deletion of exons 49 and 50 of the dystrophin gene deletion (D49-50), were transduced by lentivirus vectors harbouring a cassette designed to favor skipping of exon 51 from the dystrophin mRNA ( Figure 3A ). Such targeted skipping should generate an in-frame dystrophin mRNA sequence from the D49-50 DMD mutation ( Figure 3B ). The antisense sequences targeting potential human exon 51 were selected from several exon-internal AONs on the basis of their capacity to promote the exon skipping in over 25% of transcripts of myoblasts as previously described (Van Deutekom and van Ommen, 2003; Aartsma-Rus et al., 2005) . We used a vector incorporating the selected two sequences (23 and 20 nucleotides) located across two enhancers of splicing elements (ESE) situated in exon 51 of the DMD gene. To test whether this would induce skipping of exon 51 in vitro, CD133+ cells isolated from the blood and muscle of dystrophic D49-50 DMD patients were transduced with the U7 exon 51 lentivirus vector. Total mRNA was collected and analyzed by nested RT-PCR. In proliferation conditions, transduced dystrophic blood-derived CD133+ cells express only the 71 kDa mRNA of the ubiquitously expressed (B) Schematic representation of the D49-50 DMD deletion, which creates a codon dephasing between the exons 48 and 51 (black circle), and the expected link generated by skipping exon 51.
(C) Evaluation of the exon skipping in nontransduced and transduced D49-50 DMD blood (lanes 1 and 3, respectively)-and muscle (lanes 2 and 4, respectively)-derived CD133+ cells was performed by nested PCR (SM, size markers). Muscle and blood blanks (lanes 5 and 6, respectively) were used as controls.
(D) Sequencing of the skipped band confirms splicing of exons 48 to 52 after U7exon51 transduction. (E) Schematic map showing the five major human dystrophin isoforms and the human specific primers used to distinguish the isoforms. (F) PCR results from blood-and muscle-derived CD133+ cells after 7 days of culture in proliferation (stem-cell-conditioned) and differentiation (myogenic-conditioned) medium. Lanes 1 to 5 correspond to the expression of the different dystrophin isoforms indicated in (E). Lane 6 corresponds to the amplification of the b-actin gene as a standard. Only in myogenic conditions did the human transduced DMD blood-and muscle-derived CD133+ cells express the full length dystrophin isoform mRNA.
dystrophin isoform ( Figure 3E ). In these same culture conditions, however, transduced CD133+ cells derived from dystrophic muscle express the 71 kDa, 116 kDa, and 140 kDa dystrophin mRNA isoforms ( Figure 3F ). To test whether myogenesis promotes expression of the full-length dystrophin isoform by the skipping of the exon 51, transduced dystrophic blood-derived CD133+ cells were cocultured with murine myoblasts (ratio 1/50), whereas muscle-derived CD133+ cells were cultured in low-serum conditions. After 14 days of culture in these myogenic conditions, both dystrophic CD133+ cell populations generated the full-length dystrophin isoform mRNA and efficient exon-skipping as revealed by RT-PCR analysis ( Figure 3C ) and DNA sequencing ( Figure 3D ).
Genetically Engineered Blood-or Muscle-Derived CD133+ Dystrophic Cells Participate in Skeletal Muscle Regeneration of Dystrophic Mice after In Vivo Transplantation
In these experiments, we investigated whether genetically engineered dystrophic human CD133+ progenitors isolated from blood or muscle can exhibit in vivo myogenic properties after implantation into the muscle of adult mouse recipients. 2 3 10 4 dystrophic CD133+ cells isolated from the blood and muscle were transduced with the U7 exon 51 lentivirus vector and injected 24 hr later into the right TA muscle of 24 scid/mdx mice. Twentyone and 45 days postinjection, the transplanted muscles were harvested and characterized by immunohistochemistry. We counted the donor human lamin A/C-positive cells in all the serial sections of injected TA muscles. Forty-five days after transplantation, muscles of animals injected with blood-derived, transduced CD133+ cells contained numerous mononucleated human lamin A/Cpositive cells in the interstitial spaces, 4.5 + 0.7% of which coexpressed the CD31 and 5.6 + 1.2% of which coexpressed VE-cadherin, markers of endothelial cells (data not shown). Transplantation of muscle-derived transduced CD133+ cells produced similar results: 5 + 1.2% of the total human lamin A/C positive cells coexpressing endothelial markers (data not shown). To investigate whether blood-and muscle-skipped CD133+ cells could enter the satellite cell niche beneath the basal lamina of host fibers 45 days after transplantation, we stained for M-cadherin, laminin, and human lamin A/C. Of the human lamin A/C-positive donor cells, 7 ± 2.2% of those derived from CD133+ blood cells and 9 ± 1.4% of those derived from CD133+ muscle cells expressed M-cadherin in the injected muscles. These cells were located beneath the basal lamina closely juxtaposed against skeletal muscle fibers and accounted for 1.5% of the total sublaminal nuclei per muscle section ( Figures 4D-4F ). These results strongly suggest that intramuscularly transplanted skipped blood and muscle-derived CD133-positive cells are competent to give rise to interstitial endothelial cells and to satellite cells. To confirm the in vivo ability of CD133-positive cells isolated from the blood to differentiate into human muscle fibers, RT-PCR for human M-cadherin, Myf-5, analysis of Myogenin, Pax7, MyoD, and MRF4 mRNAs was performed on muscles from scid/mdx mice, which had been injected intramuscularly. M-cadherin and Pax7 are known to be expressed in both quiescent satellite cells and myoblasts in adult muscle (Seale et al., 2000) . Human M-cadherin, Myf-5, and Pax7 were detected in all injected TA muscles, suggesting that blood and muscle-derived CD133 stem cells differentiate in vivo into satellite cells ( Figure 4C ) together with human-specific MyoD and MRF4 mRNAs (data not shown), suggesting the differentiation of the transduced cells into mature myofibers. No human transcripts were detected in the muscles of control noninjected scid/mdx. Twenty-one days after i.m. transplantation of transduced blood-and muscle-derived CD133+ cells, the number of human dystrophin positive myofibers was, respectively, 60.1 ± 32.3 (n = 6) and 90.3 ± 33.5 (n = 6) per muscle maximal cross-section area (Table 1) . By 45 days, the mean number of human dystrophin positive myofibers per muscle maximal cross-section area had increased to 136.1 ± 53.5 (n = 6) and 416.6 ± 52.8 (n = 6), respectively, suggesting a continuing recruitment of donor cells to the regenerating dystrophic muscle (Figure 4 ). Moreover, 21 days after i.m. transplantation of transduced blood-and muscle-derived CD133+ cells, the average number of human lamin A/C-positive cells/ section (51 ± 7 [n = 5] and 86 ± 3 [n = 5], respectively) was significantly (p < 0.001) reduced by 45 days (9 ± [n = 50] and 11 ± 4 [n = 5], respectively), suggesting that mononuclear cells had been recruited into muscle fibers. In all injected muscles, many of the human dystrophinpositive fibers expressed the antihuman lamin A/C (data not shown). The clusters of dys+ fibers in muscles injected with blood and muscle-derived transduced CD133+ stem cells were also positive for a-sarcoglycans and b-sarcoglycans ( Figure 5 ). Thus, the reexpression of an in-frame human dystrophin is sufficient to assemble the dystrophin-associated protein complex ( Figure 5 ). To confirm the reestablishment of a truncated but functional human dystrophin in positive fibers, we extracted total mRNA and performed nested RT-PCR to verify the effect of the skipping of the DMD dystrophin mRNA. We found a conspicuous exon 51-skipped transcript in muscles injected with transduced blood-or muscle-derived CD133+ cells ( Figure 4A ), confirming that the clusters of positive fibers mainly represented the consequence of exon-51 skipped human dystrophin mRNA. CD133À cells isolated from the blood and muscle dystrophic tissues and transduced with the U7 exon 51 lentivirus were also transplanted into the TA of 6 scid/mdx mice. The samples from the muscles injected with the blood CD133-negative fraction did not show any skipping. In contrast, the muscles injected with the transduced muscle-derived CD133À cells showed a faint skipped band ( Figure 4A ), which probably derived from skipping of the dystrophin mRNA originating from the donor CD133À myoblasts. In addition, we verified skipping of exon 51 in vivo by sequence analysis showing the linkage between exons 48 and 52 ( Figure 4B ).
Together, these results demonstrate that lentivirally transduced CD133+ cells issuing either from DMD blood or skeletal muscle participate in regeneration of dystrophic muscle fibers after intramuscular injection and that the transduced plasmid efficiently skips exon 51 of the human dystrophin gene. The possibility that injected CD133-positive cells may revert, at least in part, to the dystrophic phenotype was examined by morphometric analysis of hematoxylin and eosin-stained muscle sections from i.m. injected and noninjected scid/mdx. Untreated scid/ mdx muscles showed classic signs of muscular dystrophy, including hypertrophic fibers, small regenerating fibers, necrosis, centrally located nuclei, and occasional fibrosis (Torrente et al., 2004) . Muscles of scid/mdx animals injected with transduced blood-and muscle-derived CD133+ cells showed a marked decrease in these dystrophic characteristics ( Figures 4J-4M) . The cross-sectional area of myofibers generated by CD133+ cells derived from blood (1655 ± 163; n = 5) and muscle (1781 ± 99; n = 5) was significantly larger (p < 0.001, Student's t test) than that of untreated scid/mdx muscles (1243 ± 122; n = 5). Moreover, the coefficient of variance in myofiber diameter was smaller (206 ± 13) within the injected muscle area than within uninjected scid/mdx muscles examined (512 ± 34) (p < 0.001, Student's t test). Another indicator of ongoing regeneration in muscular dystrophy is the increase in the percentage of myofibers with centrally located nuclei. High frequencies of centrally located nuclei (25%) were observed in all scid/mdx muscles examined, and these levels were reduced in injected muscles (around 17%).
Intra-Arterial Delivery of Genetically Engineered Muscle CD133+ Dystrophic Cells Is Followed by Functional Recovery of Dystrophic Mice
To determine whether transduced DMD muscle-derived CD133+ cells are also capable of engraftment and myogenic differentiation after intravascular injection, we injected the scid/mdx mice in both femoral arteries with these cells. Human lamin A/C-positive mononuclear cells were detected within the quadriceps (QD), extensor longus digitorum (EDL), and TA muscles of all intra-arterially injected animals. Several areas of the QD, EDL, and TA muscles expressed human dystrophin (Figure 6 ). In this experiment, the number of human dystrophin-positive myofibers was variable between the different muscles of the injected legs, and the TA muscles showed the highest one (Table 1) . In all injected muscles, most of the human dystrophin-positive muscle fibers expressed human lamin A/C. Moreover, human dystrophin positive fibers coexpressed the a-and b-sarcoglycan membrane proteins ( Figure 6 ). To analyze whether injected transduced DMD muscle-derived CD133+ cells may revert at least in part the dystrophic phenotype, we performed morphometric analysis of hematoxylin and eosin-stained muscle sections from intra-arterially injected scid/mdx mice. The value of the area of muscle fibers of the QD-and EDL-injected muscles (1600-1750 mm) was similar to that observed in uninjected QD and EDL muscles (1550-1700 mm). However, the value area of muscle fibers of the TA injected with the transduced DMD muscle-derived CD133+ cells was comprised between 1700 and 1900 mm. The variance coefficient of muscle fibers area was between 60 and 70 in TA injected, whereas it was between 40-65 and 30-50 in QD and EDL, respectively. All these data demonstrate the ability of transduced DMD muscle-derived CD133+ cells to restore dystrophin expression and reduce the muscle damage in the dystrophic mouse muscles following intra-arterial transplantation. To assess whether the expression of dystrophin and the improvement in the signs of muscular dystrophy indicated by morphometric analysis produced sustained recovery of muscle function, we evaluated the endurance capacity of injected mice and studied the physiology of injected limb muscles. Muscle function was evaluated in vitro by measuring tetanic force of isolated injected TA and EDL muscles and in vivo by using treadmill exhaustion tests. In scid/mdx mice, a significant loss in normalized tetanic force was observed in both muscles in comparison with WT ( Figures 6B and 6C) . In TA, the change in tetanic force appeared significantly counteracted by intra-arterial Results are expressed as number of human lamin A/C positive cells (Lamin A/C+), human dystrophin positive (Dys3+) fibers, human Dys3/lamin A/C positive (Dys3/LamA/C+) cells per section of tibialis anterior muscle tissue (±SD) in a longitudinal dimension of about 800 mm. after intramuscular injection (I.M.) and per section of tibialis anterior, quadriceps, and soleus muscle tissue (±SD) after intra-arterial injection (I.A.) *p < 0.01.
injection of transduced DMD muscle CD133+ cells, whereas no statistical change was observed in EDL ( Figure 6B ). Intra-arterial injection was also associated with an overall amelioration of the endurance capacity of the mice which showed intermediate time to exhaustion between WT and untreated littermates ( Figure 6D ).
DISCUSSION
In this work, we isolated DMD CD133+ cells and characterized their ability to express an exon-skipped version of human dystrophin after transduction with a lentivirus carrying a construct designed to skip exon 51 (Goyenvalle Cell Stem Cell Denti et al., 2006) . We also examined their ability to participate in muscle regeneration on in vivo transplantation into scid/mdx mice model. Two distinct CD133+ cell populations were used, one from blood and one from skeletal muscle. The myogenic potential of the blood-derived CD133+ cells was demonstrated in our previous work (Torrente et al., 2004) . Here, we show that the muscle-derived CD133+ stem cells also have the potential to differentiate toward both the muscle lineage and the endothelium lineages. Thus, we could compare the in vivo muscle differentiation of these two transplanted stem cell populations. The D49-50 DMD deletion was chosen to test the capacity of the exon-skipping strategy to restore open reading frame to the dystrophin mRNA sequence in CD133+ stem cells. Theoretically skipping exon 51 in this context should eliminate the original frameshift, revealing a correct reading frame between exon 48 and exon 52. Targeted U7-based expression plasmids based on ESE antisense oligonucleotides sequences, previously observed to skip Exon 51 efficiently (Van Deutekom and van Ommen, 2003) , were packaged in lentiviral vectors. In vitro transductions permitted testing of the capacity of our lentivirus vectors to efficiently deliver the cassette and to skip the exon 51 in D49-50 DMD-cultured cells. The skipped blood-and muscle-derived D49-50 stem cells were also able to fuse in vivo with regenerative fibers and not only express a functional human dystrophin but also restructure the dystrophin-associated protein complex as shown by plasmalemmal reexpression of a and b-sarcoglycans proteins. In this study, genetically engineered DMD muscle-derived CD133+ cells showed a better muscle regeneration in terms of spreading and numbers of positive fibers in comparison with the results obtained with blood-derived stem cells. Although the number of human lamin A/C-positive cells decrease between 21 and 45 days after intramuscular injection of transduced, blood-or muscle-derived CD133-positive cells, this was accompanied by a large increase in the expression of human dystrophin, suggesting that these genetically engineered cells, after fusion with host regenerating myofibers, may protect them against further cycles of degeneration and regeneration. Our results show too that human genetically engineered DMD blood-and muscle-derived CD133+ can become located beneath the basal lamina and distributed along freshly isolated fibers where they express M-Cadherin, all indicating that they can differentiate into satellite cells within the recipient dystrophic skeletal muscle. Further evidence that genetically engineered human DMD muscle-or blood-derived CD133-positive cells participate actively to muscle regeneration and contribute replenish the pool of satellite cells is the finding by RT-PCR in injected muscles of scid/mdx, of expression of human Myf5, Pax7, and M-cadherin. Together, these data provide strong evidence of the in vivo myogenic differentiation of the engineered D49-50 blood-and muscle-derived CD133+ stem cells and of their ability to participate in muscle regeneration in DMD muscles. However, intramuscular transplantations lead only to local and focused regeneration, whereas DMD pathology affects the whole body musculature. Its effective treatment requires methods to distribute the injected cells to these dispersed sites. To circumvent this problem, we performed intra-arterial injections of transduced DMD muscle CD133+ stem cells into dystrophic individuals. We selected the muscle the engineered D49-50 musclederived CD133+ stem in relation to their robust myogenic capacity. The data on the recovery of muscle force and endurance after the intra-arterial transplantation of these cells strongly suggest that cell spreading by this approach ameliorates morphology and can significantly restore skeletal muscle function toward normal. Our approach of using exon-skipping for the expression of human dystrophin within the DMD CD133+ cells should allow the use of the patient's own stem cells, thus minimizing the risk of immunological graft rejection (Riviè re et al., 2006) . Nevertheless, for clinical application, the combination of gene and stem cell therapy approaches does raise some problems, specifically in terms of biosafety. Principal among these is the use of lentivirus vectors as shuttles to correct the genetic defect into DMD stem cells prior to in vivo transplantation. Hazardous integration of the provirus can theoretically disturb the control of some housekeeping genes or tumor suppressor genes, and for clinical purposes, this risk, for instance, of developing a tumor after in vivo injection has to be carefully addressed. The performance of additional research focused on exon skipping will substantially enhance our understanding of the mechanisms underlying this effect and may, thus, lead to the improvement of gene and cell therapy strategies for the treatment of Duchenne Muscular Dystrophy.
EXPERIMENTAL PROCEDURES
The U7exon51 Lentiviral Vector Construction and Production The U7exon51 construct was engineered from the previously described U7smOPT-SD23/BP22 (Goyenvalle et al., 2004) . Antisense sequences targeting the mouse exon 23 were replaced by antisense sequences targeting potential human exon 51 internal splicing enhancer (ESE) as previously described (Aartsma-Rus et al., 2002): h51AON1, 5 0 -TCAAGGAAGATGGCATTTCT-3 0 and h51A ON2, 5 0 -CCTCTGTGATTTTATAACTTGAT-3 0 (Figure 3 ). The resulting U7smOPT-exon51-AON1/2 fragment was then introduced in a lentiviral vector construct. All the lentiviral vectors were based on the pRRL-cPPT-hPGKeGFP-WPRE constructs (VandenDriessche et al., 2002) . To enlarge the vector tropism, lentiviral vectors were pseudotyped with the VSV-G virus and generated by transfection into 293T cells of the plasmid pCMVDR8.74, as previously described (Zufferey et al., 1997) . The infectious particles titer (ip/ml) was determined by quantitative real-time PCR genomic DNA of transduced cells as described elsewhere (Charrier et al., 2005) .
Lentiviral Vector Transduction 10
7 to 10 8 ip/ml were used to transduce blood-and muscle-derived CD133+ cells. 2 3 10 4 to 4 3 10 4 cells were plated per well in 96 wells tissue culture dishes. Vector transduction was transferred in 100 ml of DMEM supplemented with 10% FCS. Four hours posttransduction, the medium was diluted by adding 200 ml per well of previous medium. The dishes were incubated for 24 hr at 37 C and 5% CO 2 before washing and in vivo transplantation or in vitro studies (cocultures, molecular analysis).
Blood and Muscle CD133 Stem Cell Isolation Blood CD133+ cells were collected from peripheral blood of normal or DMD patients and muscle CD133+ cells were collected from skeletal muscle biopsies of normal or DMD patients, after informed consent was obtained, according to the guidelines of the Committee on the Use of Human Subjects in Research of the Policlinico Hospital of Milan (Milan, Italy) . The protocol of cell isolation was previously described (Torrente et al., 2004) , while primary human muscle cells were obtained by enzymatic dissociation of biceps brachii muscle biopsies. Mononuclear cells from muscle were then processed through the MACS magnetic separation column (Miltenyi Biotech). After determination of the purity of the CD133+ cells, we plated the cells in the presence of a proliferation medium (PM) composed of DMEM/F-12 (1:1); 20% FBS, including HEPES buffer (5 mM), glucose (0.6%), sodium bicarbonate (3 mM), and glutamine (2 mM); SCF (100 ng/ml; TEBU, Frankfurt, Germany); VEGF (50 ng/ml; TEBU); and LIF (20 ng/ml; R&D Systems, Inc). The purity of muscle CD133-selected cells was determined for each isolation experiment. Cell viability was performed using 7-Amino-actinomycin D (1:50, Santa Cruz) overnight at 4 C. After washing with PBS, cells were incubated with FITC-conjugated goat anti-mouse IgG for 1 hr at room temperature (RT) and examined by epifluorescence microscopy. Western blot conditions were performed as previously described (Torrente et al., 2004) . Total RNA was extracted from cells by TrizolReagent (Invitrogen). First-strand cDNA was prepared by using Super Script First Strand Synthesis System for RT-PCR (Invitrogen, Life Technologies), starting from 2 mg total RNA with oligo(dT) 12-18 primers. For direct amplification of human markers, primers were specifically designed in nonhomology region of human-mouse mRNA sequences as previously described (Torrente et al., 2004 for 1 min. Human muscle-derived CD133+ cells were analyzed for their release of angiogenic factors on Angiokit (TCS CellWorks Ltd., Buckingham, UK). Briefly, the 3-day-old medium from human muscle-derived CD133+ cells was added at various dilutions (1:1, 1:2, and 1:3) to the seeded human endothelial cells (HUVEC) in a 24-well plate. Control wells that received no conditioned medium were cultured in the presence of VEGF (2 ug/ml) and Suramin (2 mM). Cultures were monitored daily for the tubule formation and fixed for immunohistochemistry analysis after 12 days of culture. Staining procedure for the expression of CD31 was performed as previously described (Bello et al., 2004) . After the immunostaining, the degree of angiogenesis was assessed using the TCS ''AngioSys'' software package (TCS CellWorks, Cat No. ZHA-1800). We analyzed the total pixel numbers in six independent microscopic fields (403). All data are expressed as a percentage of the control wells cultured in the presence of VEGF and Suramin (referred as 100%) and expressed as the mean + standard deviation (+ SD) values.
Nested and Classical RT-PCR and DNA Sequencing for the Evaluation of the Skipping To verify the in vivo skipping of the exon 51, a series of sixty 10-mm transverse cryosections obtained over the injected muscle length were collected in 1.5 ml Eppendorf tubes and mixed with 800 ml of TRIzol-reagent (Life Technology). cDNA was obtained as described above. To detect human dystrophin mRNA, nested RT-PCR was carried out with 1 mg of cDNA using, for the first amplification, a final mix (Invitrogen) constituted of 13 Taq buffer, 1.5 mM MgCl2, 0.2 mM dNTP mix, 2.5 units of the Platinium Taq DNA polymerase, 0.2 mM of forward primer Hex46F (5 0 -AGGAAGCAGATACATTGCT-3 0 ), and 0.2 mM of reverse primer Hex56R (5 0 -TGAGAGACTTTTTCCGAAGT-3 0 ). Thirty-eight cycles of amplification were used for this first PCR reaction (94 C/2 min, 92 C/1 min, 52.8 C/2 min, and 72 C/2 min). PCR products were purified using the Jetquick PCR product purification spin kit (Genomed), and a second round of amplification, using 5 ml of purified PCR, was performed in the same conditions excepted for the MgCl2 (used at 1.5 mM), and for the choice of the primers, Skip47F for the forward (5 0 -GCTTGTAAGTGCT CCCATAAGC-3 0 ) and Skip53R for the reverse (5 0 -CAGCTTCTTCCTTAGCTTCCAGC-3 0 ). The PCR products were analyzed on 2% agarose gels, and specific bands were purified for sequence analysis. Classical RT-PCR was also performed to analyze expression of myogenic markers as previously described (Torrente et al., 2004) . To investigate the expression of the most common dystrophin isoforms, we designed five different pairs of human-specific primers: dys-427 kD F(5 0 -CCTACAGGACT CAGATCTGG-3 0 ) and R(5 0 -GTCCTCTACTTCTTCCCAC C-3 0 ); dys-260 kD F(5 0 -GCATCCAGTCTGCCCAGG-3 0 ) and R(5 0 -GAGACAGGACTCTTTGGGCAG-3 0 ); dys-140 kD F(5 0 -GGATGGCATTGGGCAGCG-3 0 ) and R(5 0 -GCTCTTT TCCAGGTTCAAGTGG-3 0 ); dys-116 kD F(5 0 -CCTCCAAG GTGAAATTGAAGC-3 0 ) and R(5 0 -CTGGCTTCCAAATGGG ACC-3 0 ); dys-71 kD F(5 0 -CCACGAGACTCAAACAACTTG C-3 0 ) and R (5 0 -CTTGAGGTTGTGCTGGTCC-3 0 ) ( Figure 3E ). In transplanted and untransplanted scid/mdx muscles, the endogenous dystrophin was detected using mouse specific primers as previously described by Goyenvalle et al. (2004) . PCR was performed on cDNA samples obtained from blood and muscle CD133+ cells cultured in proliferation and differentiation conditions. To promote myogenic differentiation of the blood-derived CD133+ cells, we cocultured these cells with murine myoblasts with a ratio of 1/50. The myogenesis of muscle-derived CD133+ cells was promoted in DMEM supplemented with 5% FCS and 5% horse serum (HS).
Transplantation of the Blood-and Muscle-Derived CD133+ Cells into Immunodeficient scid/mdx Mice A breeding colony of homozygous scid/mdx mice was previously established (Torrente et al., 2004; Farini et al., 2007) . Two-month-old scid/mdx mice were anesthetized with ketamine hydrochloride (80 mg/kg) and xylazine (10 mg/kg). In the first experiments, human CD133+ cells isolated from the normal and dystrophic human muscle (2 3 10 4 cells in 7 ml of PBS) were injected into the right Tibialis Anterior (TA) muscle of 12 mice as previously described (Torrente et al., 2004) . 21 days later, muscle tissues were removed, frozen in liquid-nitrogen-cooled isopentane and cut on a cryostat into serial sections. Detection of transplanted human cells and human myofibers was performed using the anti-human lamin A/C and human spectrin antibodies as described below. In the second experiments, 2 3 10 4 to 4 3 10 4 of the genetically engineered human DMD blood and muscle-derived CD133-positive or CD133-negative cells were injected into the right TA muscles of 24 scid/mdx mice. In all treated animals, muscle degeneration-regeneration was induced 24 hr prior to transplantation by an intense swimming exercise (Torrente et al., 2001 ). Three injections per transplantation were performed over the targeted muscle length. In a third experiment, transduced DMD muscle CD133+ cells were injected into both the right and left femoral artery (5 3 10 5 cells per leg) of six scid/mdx mice. At 21 and 45 days after intramuscular and intra-arterial injections, muscle tissues were removed, frozen in liquid nitrogen-cooled isopentane, and cryostat-sectioned. Serial sections of 10 mm thickness were counted at 80 mm intervals and examined by immunohistochemical analysis and hematoxylin and eosin (H&E) staining.
Immunohistochemistry Analysis of Injected Muscles
Series of 10 mm transverse cryosections cut over the scid/ mdx injected muscle length were examined by immunohistochemical and H&E staining. Detection of human dystrophin was performed with monoclonal antibodies directed against the human specific amino-terminal Dys fragment (NCL-Dys3, Novocastra Laboratories) as previously described (Torrente et al., 2004) . Rabbit anti-mouse laminin (Sigma, Saint Louis, USA) was used at the dilution of 1/100. To improve the cadherin staining, the anti-M-cadherin (Goat anti-mouse, Santa Cruz; 1:50) was used with 2 mM -Ca
2+
. Human donor nuclei were stained with monoclonal anti-human nuclear lamin A/C (1:100; Novocastra Laboratories). Detection of the dystrophin-associated complex proteins used monoclonal anti-mouse a and b-sarcoglycans (Novocastra Laboratories) to a final dilution of 1:100. Detection of the human spectrin was performed using monoclonal antibody directed against the b-chain (NCL-SPEC1, Novocastra) to a final dilution of 1:100. The effect of genetically engineered human DMD blood-and muscle-derived CD133+ cells on host dystrophic muscle regeneration was evaluated by calculating the cross-sectional myofiber area, the variance in myofiber diameter, and the percentage of myofibers with centrally located nuclei using ImageQuest software (LEICA DMIR2). Images were captured using the Leica TCS SP2 confocal system.
Mechanics of Isolated Muscles
Tibialis and extensor digitorum longus (EDL) (n = 8 each) were dissected in an oxygenated Krebs solution (95% O 2 and 5% CO 2 ) under a stereomicroscope at RT and analyzed as previously described (Rossi and Bottinelli, 2001) . Briefly, muscles, tied up at the tendons by using silk threads, were transferred to the organ baths where they were mounted between the hook of a force transducer (Grass) and the hook of a movable shaft used to adjust muscle length. The perfusion bath was filled with Krebs solution bubbled with O 2 -CO 2 mixture and kept at constant temperature (22 C). Stimulation was delivered through plate platinum electrodes connected to a Grass stimulator. Tetanic isometric contractions (400 ms; 100Hz, supramaximal amplitude) were studied at Lo (the length at which the maximal isometric force is observed). Tetanic force was normalized to muscle cross sectional area (CSA) and expressed as kN/m 2 .
Exercise Tolerance Tests
Exhaustion treadmill was used to evaluate the endurance capacity of mice. Four mice were placed on the belt of motorized treadmill (six-lane Exer 3/6 Treadmill, Columbus Instruments, Columbus, OH) supplied with shocker plates. The treadmill was run at an inclination of 0 at 5 m/min for 5 min, after which the speed was increased 1 m/min every minute. The test was then stopped when the mouse remained on the shocker plate for 20 s without any attempt to reengage the treadmill, and the time to exhaustion (expressed in minutes) was determined.
